施维雅完成对Edgewise Therapeutics肌营养不良症业务的收购-动脉网

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

PR Newswire 等信源发布 2026-07-13 20:30



可切换为仅中文







Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies.

此次收购支持施维雅在罕见神经病学领域的战略雄心，其核心产品为sevasemten，这是一种用于贝克氏肌营养不良症和杜兴氏肌营养不良症的后期研究性治疗药物。

The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs.

此次收购的资产及专家团队加强了施维雅对为存在高度未满足医疗需求的患者进行创新的承诺。

SURESNES, France

法国叙雷讷

，

July 13, 2026

2026年7月13日

/PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq:

/美通社/ -- 由基金会管理的独立国际制药集团施维雅今日宣布，已完成对Edgewise Therapeutics Inc.（纳斯达克：

EWTX

), for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments. This announcement follows regulatory clearance and customary closing conditions.

），交易总额高达26.5亿美元，包括15.5亿美元的首付款以及高达11亿美元的监管和商业里程碑付款。此公告是在获得监管批准并满足惯例交割条件后发布的。

继续阅读

View PDF

查看PDF

The acquisition significantly advances Servier's rare neurology pipeline with a late-stage asset, sevasemten, currently being investigated in a pivotal cohort in Becker muscular dystrophy (BMD), and in phase 2 in Duchenne muscular dystrophy (DMD). It also provides Servier with additional capabilities by integrating Edgewise Therapeutics' expertise to advance the development of sevasemten. .

此次收购通过引入后期资产sevasemten，显著推进了施维雅在罕见神经学领域的产品管线。该资产目前正在贝克氏肌营养不良症（BMD）的关键队列中进行研究，并在杜氏肌营养不良症（DMD）中处于二期临床试验阶段。此外，通过整合Edgewise Therapeutics的专业知识以加速sevasemten的开发，此次收购也为施维雅提供了额外的能力。

Sevasemten is an orally administered potential first-in-class fast skeletal myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced damage in individuals living with rare muscular dystrophy. BMD is a rare, X-linked genetic disorder that causes progressive muscle loss, with currently no approved treatment for patients. The loss of muscle function is irreversible and impacts patients' abilities to perform everyday activities like walking. DMD is a more severe, recessive X-linked genetic, degenerative muscle disorder beginning at birth that causes patients to lose their walking ability by their early teens.

Sevasemten 是一种口服给药的潜在首类快骨骼肌球蛋白抑制剂，旨在保护罕见肌肉营养不良症患者体内不稳定的肌肉，防止其因收缩而受损。贝克型肌营养不良（BMD）是一种罕见的 X 连锁遗传病，会导致进行性肌肉流失，目前尚无获批的治疗药物。肌肉功能的丧失是不可逆的，会影响患者执行行走等日常活动的能力。杜氏肌营养不良（DMD）是一种更为严重的隐性 X 连锁遗传性退行性肌肉疾病，自出生起发病，导致患者在青少年早期丧失行走能力。

It is the most common type of muscular dystrophy with a median life expectancy of around 30 years. .

这是最常见的肌营养不良症类型，中位预期寿命约为30年。

'Delivering precision therapies to people with rare and devastating conditions is at the heart of Servier's mission. The combination of Edgewise's expertise in muscular dystrophy with Servier's global capabilities is a major step forward to accelerate the development of innovative treatments for people living with Becker and Duchenne', said .

“为患有罕见且严重疾病的患者提供精准疗法，是施维雅使命的核心。埃奇威斯在肌营养不良症领域的专业知识与施维雅的全球能力相结合，为加速开发针对贝克氏肌营养不良和杜氏肌营养不良患者的创新疗法迈出了重要一步。”

Olivier Laureau, President of Servier.

施维雅总裁奥利维耶·洛罗。

'This acquisition is a strategic milestone in achieving our Servier 2030 ambition in rare neurology.'

“此次收购是实现我们施维雅2030年在罕见神经病学领域愿景的战略里程碑。”

'Servier's strong commitment to patients, growing focus on rare neurology, and established global capabilities position them as the optimal partner to advance the muscular dystrophy business', said

“施维雅对患者的高度承诺、对罕见神经病学领域日益增长的关注，以及成熟的全球能力，使其成为推进肌营养不良症业务发展的理想合作伙伴。”

Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise Therapeutics.

凯文·科赫博士，Edgewise Therapeutics 总裁兼首席执行官。

Contacts

联系人

Servier Group, Olympe Muller

施维雅集团，奥林普·穆勒

[email protected]

PDF -

https://mma.prnewswire.com/media/3005524/PDF.pdf

Logo -

徽标 -